Ongoing clinical studies have been conducted to inhibit the CD47–SIRPα axis using several antibodies or fusion proteins targeting CD47 and SIRPα in some solid and hematologic cancers [16]. This evidence concerns the gene SIRPA and hematopoietic and lymphoid cell neoplasm.